Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...3839404142434445464748...5960»
  • ||||||||||  Journal:  System of Criteria for Treatment Evaluation of Acromegaly in Bulgaria. (Pubmed Central) -  Aug 30, 2020   
    The here reported results provide evidence about the difficulties in maintaining both GH and IGF-1 levels inside their reference values in acromegaly treatment. Ongoing research extends the evaluation results by enabling semantic interoperability between acromegaly databases based on openEHR specification.
  • ||||||||||  Journal:  Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. (Pubmed Central) -  Aug 29, 2020   
    Patients treated with surgery or radiotherapy had a higher risk of VF progression in this cohort (P=0.030). Conclusions In this cohort of long-term well-controlled acromegalic patients, the prevalence and progression of VFs was high, showing that the deleterious effects of GH and IGF-1 excess on bone persist despite achievement of longstanding remission.
  • ||||||||||  Clinical, Journal:  Acromegaly: a clinical perspective. (Pubmed Central) -  Aug 28, 2020   
    In this study, the majority of tumors were macroadenoma, plurihormonal, and treated effectively with surgery alone or surgery with adjuvant medical or radiation therapy. More studies are needed to identify additional molecular biomarkers, tumor characteristics and imaging findings to individualize treatment and better predict treatment outcomes.
  • ||||||||||  [VIRTUAL] Acromegaly: a rare factor in (so common) Obstructive Sleep Apnea Syndrome (Poster Networking Lounge) -  Aug 16, 2020 - Abstract #ESRS2020ESRS_838;    
    It has long been recognized that the pathophysiology of OSAS involves the interaction of multiple and complex factors. The etiological study, and a targeted approach, of certain phenotypes may be the key to therapeutic success in some cases.
  • ||||||||||  Trial completion date, Trial primary completion date:  Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly (clinicaltrials.gov) -  Aug 9, 2020   
    P=N/A,  N=20, Recruiting, 
    Despite the associations between cardiovascular and sleep parameters, only minor changes in cardiovascular parameters after TSA were detected within one year of observation. Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021
  • ||||||||||  lignocaine / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  ultradian: Dynamic Hormone Diagnostics in Endocrine Disease (clinicaltrials.gov) -  Aug 8, 2020   
    P=N/A,  N=350, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021 Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020
  • ||||||||||  Trial completion date, Trial primary completion date:  Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor (clinicaltrials.gov) -  Aug 8, 2020   
    P=N/A,  N=30, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  Journal:  Serum phosphate: Does it more closely reflect the true state of acromegaly? (Pubmed Central) -  Aug 6, 2020   
    As a metabolic product which affected by the GH/IGF-1 axis, serum P appears to more closely reflect the comprehensive disease status in acromegaly. When the GH and IGF-1 levels are discordant during follow-up, perioperative change in the P level may be a potential predictor of remission.
  • ||||||||||  Clinical, Journal:  Fibroblast activation protein is a GH target: A prospective study of patients with acromegaly before and after treatment. (Pubmed Central) -  Jul 29, 2020   
    P=N/A
    Our results indicate that the immunohistochemical detection of E-cadherin might be useful in categorizing acromegaly patients based on the response to SSAs. 1)Circulating FGF21 and β-klotho do not change in response to acromegaly treatment, 2) FAP concentrations in serum decrease after disease control and correlate positively with collagen turnover markers, 3)FAP is a hitherto unrecognized GH target linked to collagen turnover.
  • ||||||||||  cabergoline / Generic mfg., Somavert (pegvisomant) / Pfizer
    Review, Journal:  Management of persistent acromegaly following primary therapy: The current landscape in the UK. (Pubmed Central) -  Jul 29, 2020   
    To add to the complexity, subtle differences exist in availability of high-cost medications used in the treatment of patients with acromegaly across the devolved nations of the UK. In this article, we discuss options for the management of persistent acromegaly following initial surgery and somatostatin analogue therapy, and explore earlier use of dopaminergics and conservative management.
  • ||||||||||  [VIRTUAL] GASTROINTESTINAL AND RENAL INVOLVEMENT IN SYSTEMIC VASCULITIS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_5541;    
    GI involvement limited to the duodenum in the setting of ANCA-MPO vasculitis is a rare condition. Moreover histopathologic confirmation of vasculitis in endoscopic biopsy samples is exceptional.
  • ||||||||||  [VIRTUAL] GASTROINTESTINAL AND RENAL INVOLVEMENT IN SYSTEMIC VASCULITIS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_3565;    
    GI involvement limited to the duodenum in the setting of ANCA-MPO vasculitis is a rare condition. Moreover histopathologic confirmation of vasculitis in endoscopic biopsy samples is exceptional.
  • ||||||||||  [VIRTUAL] GASTROINTESTINAL AND RENAL INVOLVEMENT IN SYSTEMIC VASCULITIS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_1581;    
    GI involvement limited to the duodenum in the setting of ANCA-MPO vasculitis is a rare condition. Moreover histopathologic confirmation of vasculitis in endoscopic biopsy samples is exceptional.
  • ||||||||||  [VIRTUAL] Screening for obstructive sleep apnea (OSA) in acromegaly (Pre-congress content) -  Jul 15, 2020 - Abstract #ERS2020ERS_503;    
    STOP-Bang and ESS can be used to identify acromegalic patients at high OSA risk. In patients with lower OSA risk, nocturnal pulse oximetry can exclude severe OSA, especially in controlled acromegaly.
  • ||||||||||  Review, Journal:  Surgery for Acromegaly. (Pubmed Central) -  Jul 3, 2020   
    Thus, a significant proportion of patients fail to achieve remission after surgery for whom treatment options for residual disease must be carefully considered. This review article discusses the surgical management of acromegaly and provides a summary of contemporary outcomes and current treatment controversies.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
    Review, Journal:  The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'. (Pubmed Central) -  Jul 1, 2020   
    This review focuses on the clinically relevant interplay of hypophyseal hormones and glucose homeostasis. The authors define 'hypophyseo-vigilance' as an approach which keeps the bidirectional, multifaceted interactions between the pituitary and glucose metabolism in mind while managing diabetes and pituitary disease.
  • ||||||||||  Journal:  Acromegalic Arthropathy. (Pubmed Central) -  Jun 28, 2020   
    J Orthop Sports Phys Ther 2019;49(11):864. doi:10.2519/jospt.2019.8302.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
    Journal:  MEDICAL TREATMENT LANDSCAPE FOR ACTIVE ACROMEGALY IN A PITUITARY CENTER IN ISRAEL. (Pubmed Central) -  Jun 28, 2020   
    Active acromegaly can be controlled medically in most patients, with a low rate of adverse effects. This study displays the characteristic variety of treatment options available for active acromegaly.